Skip to content

Debt-to-assets at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
0.5×0.0×
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
0.3×0.0×
Biogen logo
BiogenBIIB
0.2×0.0×
Alkermes logo
AlkermesALKS
0.4×+0.3×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
0.1×0.0×
TG Therapeutics logo
TG TherapeuticsTGTX
0.5×+0.1×

Other financials

Income statement

See full
Revenue--100%
Operating income-$105.9M-41.7%
Net income-$92.6M-33.6%
EPS (diluted)-$3.20+2.7%

Balance sheet

See full
Cash & equivalents$536.7M+223%
Total debt$1.4M+31.3%
Total equity$1.4B+221%
Total assets$1.5B+205%

Cash flow

See full
Operating cash flow-$86.2M-62.5%
CapEx$62.0K
Free cash flow-$86.2M-62.6%

Valuation

See full
Market cap$7.87B+1,075%
Enterprise value$7.34B+1,309%

Profitability

See full
Operating margin-3,927.5%-1,497pp
Net margin-3,658.5%-1,388pp
FCF margin-3,067.4%-1,030pp

Returns & leverage

See full
Return on equity-35.3%-10.9pp
Debt / equity0.0×
Current ratio15.9×+7.4×

Where this comes from

Calculated from Praxis Precision Medicines, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Praxis Precision Medicines, Inc.'s debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Praxis Precision Medicines, Inc.'s debt-to-assets?
Praxis Precision Medicines, Inc. (PRAX) reported debt-to-assets of 0× in Q1 2026.
How has Praxis Precision Medicines, Inc.'s debt-to-assets changed year-over-year?
Praxis Precision Medicines, Inc.'s debt-to-assets decreased by 54.5% year-over-year, from 0× to 0×.
What is the long-term trend for Praxis Precision Medicines, Inc.'s debt-to-assets?
Over 5 years (2020 to 2025), Praxis Precision Medicines, Inc.'s debt-to-assets has grown at a -47.5% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.